Live symbol workspace

SLNO market intelligence

Chart context, AI evidence, sentiment, related news, and verified outcome history are grouped into one asset dossier.

Current $39.49

Trend Flat

Sentiment Neutral

{# Only render the live technical grid when the AI analysis carries real, non-placeholder data. Sentinel payloads (data_status error/collecting, current_price 0) are handled by the Asset Intelligence Dossier below, which degrades to a calm branded empty state instead of "0%" widgets. #}

Detailed Market Analysis

Key Levels

Support

$37.52

Resistance

$41.46

Volume & Momentum

Volume

Weak

0.8x avg

Momentum

0%

Weak

Technical Context

Current price

$39.49

RSI context

50

Market Sentiment

50

Neutral

Stock Metrics

Daily Vol

0%

VIX Est

20

Weekly

0%

Asset Intelligence Dossier

Provider track record

Not enough scored provider calls yet for this asset.

Confidence trend

30%

— 0.0 pts vs previous week

Avg confidence across 9 calls in the last 7 days

What sources say

No news-sourced AI calls in the last 30 days.

Insider Trading

Refreshing insider trades from FinViz…

Technical Observations

Refreshing technical observations from FinViz...

SLNO News Intelligence (2 articles)

AI-curated news influencing SLNO price, sentiment, and trend

Explore All SLNO News with AI Analysis

Stocks

3 months ago

Neurocrine wants to develop new obesity drugs. It’s making an acquisition to accelerate that move.

Soleno Therapeutics stock is soaring on Monday in premarket after a report that Neurocrine is nearing a deal to buy …

Impact on SLNO: Soleno Therapeutics' stock is soaring in premarket trading, with potential for a …

Neurocrine's potential acquisition of Soleno Therapeutics is driving a surge in Soleno's stock price, with … High (80%)

View full analysis →

MarketWatch 80% confidence

Global Markets & Finance

3 months ago

Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment

Soleno Therapeutics makes first commercialised drug for extreme hunger caused by Prader-Willi syndrome

Impact on SLNO: The acquisition is likely to have a positive impact on Neurocrine's stock …

Neurocrine is nearing a $2.5bn-plus deal to acquire Soleno Therapeutics, the biotech company behind the … High (80%)

View full analysis →

Financial Times 80% confidence